Haemopoietic stem cell transplantation for acute lymphoblastic leukaemia

Cancer Treatment Reviews

Volumn 29, Issue 1, 2003, Pages 3-10

  Popat, Uday ^a   Carrum, George ^a   Heslop, Helen E ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LONG TERM CARE; LYMPHOCYTE DEPLETION; NONHUMAN; PERIPHERAL BLOOD STEM CELL; REVIEW; T LYMPHOCYTE; TREATMENT FAILURE; UMBILICAL CORD BLOOD;

EID: 0037303242     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(02)00092-0     Document Type: Review

References (60)

1. Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukaemia by gene expression profiling. Cancer Cell 2002; 1: 133-143.
2. Pui CH, Evans WE. Acute lymphoblastic leukaemia. N Engl J Med 1998; 339: 605-615.
3. Wheeler KA, Richards SM, Bailey CC, et al. Bone marrow transplantation versus chemotherapy in the treatment of very high-risk childhood acute lymphoblastic leukaemia in first remission: results from Medical Research Council UKALL X and XI. Blood 2000; 96: 2412-2418.
4. Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukaemia. N Engl J Med 2000; 342: 998-1006.
5. Pui CH, Gaynon PS, Boyett JM, et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 2002; 359: 1909-1915.
6. www.ibmtr.org. Int Bone Marrow Transplant Registry 2002.
7. Sebban C, Lepage E, Vernant JP, et al. Allogeneic bone marrow transplantation in adult acute lymphoblastic leukaemia in first complete remission: a comparative study. French Group of Therapy of Adult acute Lymphoblastic Leukaemia. J Clin Oncol 1994; 12: 2580-2587.
8. Chao NJ, Forman SJ, Schmidt GM, et al. Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukaemia during first complete remission. Blood 1991; 78: 1923-1927.
9. Thiebaut A, Vernant JP, Degos L, et al. Adult acute lymphocytic leukaemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Haematol Oncol Clin North Am 2000; 14: 1353-1366.
10. Barrett AJ, Horowitz MM, Pollock BH, et al. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukaemia in a second remission. N Engl J Med 1994; 332: 823-824.
11. Harrison G, Richards S, Lawson S, et al. Comparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial. MRC Childhood Leukaemia Working Party. Ann Oncol 2000; 11: 999-1006.
12. Wheeler K, Richards S, Bailey C, Chessells J. Comparison of bone marrow transplant and chemotherapy for relapsed childhood acute lymphoblastic leukaemia: the MRC UKALL X experience. Medical Research Council Working Party on Childhood Leukaemia. Br J Haematol 1998; 101: 94-103.
13. Wagner JE, Anasetti C, Kollman C, et al. Unrelated donor bone marrow transplantation in 5075 patients with malignant and non-malignant disease: Effect of graft-versus-host-disease prophylaxis on treatment outcome. 2002 [in press].
14. Goldman FD, Rumelhart SL, DeAlacron P, et al. Poor outcome in children with refractory/relapsed leukaemia undergoing bone marrow transplantation with mismatched family member donors. Bone Marrow Transplant 2000; 25: 943-948.
15. Biggs JC, Horowitz MM, Gale RP, et al. Bone marrow transplants may cure patients with acute leukaemia never achieving remission with chemotherapy. Blood 1992; 80: 1090-1093.
16. NMDP online. www.nmdp.org 2002.
17. Hongeng S, Krance RA, Bowman LC, et al. Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia. Lancet 1997; 350: 767-770.
18. Oakhill A, Pamphilon DH, Potter MN, et al. Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission. Br J Haematol 1996; 94: 574-578.
19. Saarinen-Pihkala UM, Gustafsson G, Ringden O, et al. No disadvantage in outcome of using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lymphoblastic leukaemia in second remission. J Clin Oncol 2001; 19: 3406-3414.
20. Al Kasim FA, Thornley I, Rolland M, et al. Single-centre experience with allogeneic bone marrow transplantation for acute lymphoblastic leukaemia in childhood: similar survival after matched-related and matched-unrelated donor transplants. Br J Haematol 2002; 116: 483-490.
21. Woolfrey AE, Anasetti C, Storer B, et al. Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukaemia in children. Blood 2002; 99: 2002-2008.
22. Bunin N, Carston M, Wall D, et al. Unrelated marrow transplantation for children with acute lymphoblastic leukaemia in second remission. Blood 2002; 99: 3151-3157.
23. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukaemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339: 1186-1193.
24. Handgretinger R, Schumm, M, Lang P, et al. Transplantation of megadoses of purified haploidentical stem cells. Ann N Y Acad Sci 1999; 872: 351-361.
25. Guinan EC, Boussiotis VA, Neuberg D, et al. Transplantation of anergic histoincompatible bone marrow allografts [see comments]. N Engl J Med 1999; 340: 1704-1714.
26. Weisdorf DJ, Billett AL, Hannan P, et al. Autologous versus unrelated donor allogeneic marrow transplantation for acute lymphoblastic leukaemia. Blood 1997; 90: 2962-2968.
27. Henslee-Downey PJ, Abhyankar SH, Parrish RS, et al. Use of partially mismatched related donor extends access to allogenic marrow transplant. Blood 1997; 89: 3864-3872.
28. Attal M, Blaise D, Marit G, et al. Consolidation treatment of adult acute lymphoblastic leukaemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group. Blood 1995; 86: 1619-1628.
29. Bensinger WI, Weaver CH, Appelbaum FR, et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85: 1655-1658.
30. Korbling M, Przepiorka D, Huh YO, et al. Allogeneic blood stem cell transplantation for refratory leukaemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659-1665.
31. Bensinger W, Martin P, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with haematologic cancers. N Engl J Med 2001; 344: 175-181.
32. Couban S, Simpson DR, Barnett MJ, et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002; 100: 1525-1531.
33. Champlin RE, Schmitz N, Horowitz MM, et al. Blood stem cells compared with bone marrow as a source of haematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 2000; 95: 3702-3709.
34. Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998; 339: 1565-1577.
35. Gluckman E, Rocha V, Boyer-Chammard A, et al. Outcome of cord-blood transplantation from related and unrelated donors. N Engl J Med 1997; 337: 373-381.
36. Rocha V, Cornish J, Sievers E, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukaemia. Blood 2002; 97: 2962-2971.
37. Locatelli F, Rocha V, Chastang C, et al. Factors associated with outcome after cord blood transplantation in children with acute leukaemia. Eurocord-Cord Blood Transplant Group. Blood 1999; 93: 3662-3671.
38. Davies SM, Ramsay NK, Klein JP, et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukaemia. J Clin Oncol 2000; 18: 340-347.
39. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant haematologic diseases. Blood 1998; 91: 756-763.
40. Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with haematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631-637.
41. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-2824.
42. Storb R, Yu C, Deeg HJ, et al. Current and future preparative regimens for bone marrow transplantation in thalassemia. Ann N Y Acad Sci 1998; 850: 276-287.
43. Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation [in process citation]. Blood 2000; 96: 2419-2425.
44. Wulf GG, Rill DR, Luo K-L, et al. Complement fixing monoclonal antibodies to facilitate stem cell transplantation in mice. Ann N Y Acad Sci [in press].
45. Nash RA, Pineiro LA, Storb R, et al. FK506 in combination with methotrexate for the prevention of graft- versus-host disease after marrow transplantation from matched unrelated donors. Blood 1996; 88: 3634-3641.
46. Champlin RE, Passweg JR, Zhang MJ, et al. T-cell depletion of bone marrow transplants for leukaemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood 2000; 95: 3996-4003.
47. Porter DL, Antin JH. The graft-versus-leukaemia effects of allogeneic cell therapy. Annu Rev Med 1999; 50: 369-386.
48. Ottmann OG, Wassmann B, Pfeifer H, et al. Activity of the ABL-Tyrosine Kinase Inhibitor Glivec (STI571) in Philadelphia Chromosome Positive Acute Lymphoblstic Leukaemia (PH+ ALL) Relapsing after Allogeneic stem cell transplantation (allo-SCT). Blood 2002; 98(11): 589a.
49. Uzunel M, Mattsson J, Jaksch M, Remberger M, Ringden O. The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia. Blood 2001; 98: 1982-1984.
50. Locatelli F, Zecca M, Rondelli R, et al. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukaemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. Blood 2000; 95: 1572-1579.
51. Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E. Feasibility of immunotherapy of relapsed leukaemia with ex vivo- generated cytotoxic T lymphocytes specific for haematopoietic system-restricted minor histocompatibility antigens. Blood 1999; 93: 2336-2341.
52. Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukaemia cells by a CD8(+) cytotoxic T- lymphocyte clone specific for WT1 peptide. Blood 2000; 95: 286-293.
53. Cardoso AA, Seamon MJ, Alfonso HM, et al. Ex vivo generation of human anti-pre-B leukaemia-specific autologous cytolytic T cells. Blood 1997; 90: 549-561.
54. Dilloo D, Bacon K, Holden W, et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med 1996; 2: 1090-1095.
55. Rousseau RF, Bollard CM, Heslop HE. Gene therapy for paediatric leukaemia. Expert Opin Biol Ther 2001; 1: 663-674.
56. Dekker AW, Vant Veer MG, Van der Holt B, et al. Postremission treatment with autologous stem cell transplantation (Auto-SCT) or Allogeneic stem cell trans- plantation (Allo-SCT) in adults with Acute Lymphoblastic Leukaemia (ALL). A Phase II Clinical trial (HOVON 18 ALL). Blood 2002; 98.
57. Rowe JM, Richards SM, Burnett AK, et al. Favorable results of Allogeneic Bone Marrow Transplantation (BMT) for Adults with Philadelphia (Ph)-chromosome-negative Acute Lymphoblastic Leukaemia (ALL) in first complete remission (CR): results from the International ALL trial (MRC UKALL XII/ECOG E2993). Blood 2001; 98.
58. Goldstone AH, Prentice HG, Durrant JI, et al. Allogeneic transplant (related or unrelated donor) is the preferred treatment for adult Philadelphia chromosome positive (Ph+) Acute Lymphoblastic Leukaemia (ALL). Results from the international ALL trial (MRC UKALL XII/ECOG E2993). Blood 2002: 98.
59. Zhang MJ, Hoelzer D, Horowitz MM et al. Long-term follow-up of adults with acute lymphoblastic leukaemia in first remission treated with chemotherapy or bone marrow transplantation: the Acute Lymphoblastic Leukaemia Working Committee. Ann Int Med 1995; 123: 428-431.
60. Oh H, Gale RP, Zhang MJ, et al. Chemotherapy vs HLA-identical sibling bone marrow transplants for adults with acute lymphoblastic leukaemia in first remission. Bone Marrow Transplant 1998; 22: 253-257.